EA201790811A1 - Содержащие бактерии композиции и способы для улучшения видов поведения при нарушениях неврологического развития - Google Patents

Содержащие бактерии композиции и способы для улучшения видов поведения при нарушениях неврологического развития

Info

Publication number
EA201790811A1
EA201790811A1 EA201790811A EA201790811A EA201790811A1 EA 201790811 A1 EA201790811 A1 EA 201790811A1 EA 201790811 A EA201790811 A EA 201790811A EA 201790811 A EA201790811 A EA 201790811A EA 201790811 A1 EA201790811 A1 EA 201790811A1
Authority
EA
Eurasian Patent Office
Prior art keywords
disorders
methods
compositions containing
subject
containing bacteria
Prior art date
Application number
EA201790811A
Other languages
English (en)
Inventor
Антуанетт Бейли
Саркис К. Мазманян
Пол Х. Паттерсон
Original Assignee
Калифорния Инститьют Оф Текнолоджи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Калифорния Инститьют Оф Текнолоджи filed Critical Калифорния Инститьют Оф Текнолоджи
Publication of EA201790811A1 publication Critical patent/EA201790811A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A61K2035/115—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

Некоторые варианты реализации настоящего изобретения включают виды бактерий для применения для лечения одного или более симптомов расстройства аутического спектра (РАС) и/или шизофрении у субъекта, нуждающегося в указанном лечении. Субъект, нуждающийся в указанном лечении, может иметь профиль кишечной микробиоты, характерный для взрослого. Виды бактерий могут включать бактерий Bacteroides(например, В. fragilis, В. thetaiomtaomicronи/или В. vulgatus)и/или Enterococcus(например, Е. faecalis, E. faecium, E. hirae, E. avium, E. durans, E. gallinarumили Е. casseliflavusЛечение может приводить к улучшению одного или более связанных с РАС видов поведения у субъекта.
EA201790811A 2014-10-30 2015-10-28 Содержащие бактерии композиции и способы для улучшения видов поведения при нарушениях неврологического развития EA201790811A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462072905P 2014-10-30 2014-10-30
PCT/US2015/057891 WO2016069795A2 (en) 2014-10-30 2015-10-28 Compositions and methods comprising bacteria for improving behavior in neurodevelopmental disorders

Publications (1)

Publication Number Publication Date
EA201790811A1 true EA201790811A1 (ru) 2017-11-30

Family

ID=55851462

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201790811A EA201790811A1 (ru) 2014-10-30 2015-10-28 Содержащие бактерии композиции и способы для улучшения видов поведения при нарушениях неврологического развития

Country Status (11)

Country Link
US (4) US10111914B2 (ru)
EP (2) EP3998074A1 (ru)
JP (1) JP2017535542A (ru)
KR (1) KR20170086492A (ru)
CN (1) CN107106616A (ru)
AU (2) AU2015339284B2 (ru)
BR (1) BR112017009004A2 (ru)
CA (1) CA2966360C (ru)
EA (1) EA201790811A1 (ru)
HK (1) HK1243639A1 (ru)
WO (1) WO2016069795A2 (ru)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3072524T1 (en) 2010-10-07 2018-04-30 California Institute Of Technology Probiotic anti-autism therapy
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
US10039777B2 (en) 2012-03-20 2018-08-07 Neuro-Lm Sas Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
JP6679309B2 (ja) 2012-08-29 2020-04-15 カリフォルニア インスティチュート オブ テクノロジー 自閉症スペクトラム障害の診断および処置
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
US10111914B2 (en) 2014-10-30 2018-10-30 California Institute Of Technology Compositions and methods comprising bacteria for improving behavior in neurodevelopmental disorders
CA2966363A1 (en) 2014-10-30 2016-05-06 California Institute Of Technology Compositions and methods comprising bacteria for improving behavior in neurodevelopmental disorders
DK3193901T3 (en) 2014-12-23 2018-05-28 4D Pharma Res Ltd PIRIN POLYPEPTIDE AND IMMUNMODULATION
CN108138122B (zh) 2014-12-23 2021-09-21 4D制药研究有限公司 免疫调控
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
DK3307288T3 (da) 2015-06-15 2019-10-07 4D Pharma Res Ltd Sammensætninger omfattende bakteriestammer
WO2016203223A1 (en) 2015-06-15 2016-12-22 4D Pharma Research Limited Compositions comprising bacterial strains
PT3240554T (pt) 2015-06-15 2019-11-04 4D Pharma Res Ltd Blautia stercosis e wexlerae para uso no tratamento de doenças inflamatórias e autoimunes
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
PL3209310T3 (pl) 2015-11-20 2018-08-31 4D Pharma Research Limited Kompozycja zawierająca szczepy bakteryjne
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
BR112018067689A2 (pt) 2016-03-04 2019-01-08 4D Pharma Plc composições compreendendo cepas bacterianas do gênero blautia para tratar a hipersensibilidade visceral
US11116804B2 (en) 2016-03-14 2021-09-14 Holobiome, Inc. Modulation of the gut microbiome to treat mental disorders or diseases of the central nervous system
WO2017205302A1 (en) 2016-05-23 2017-11-30 California Institute Of Technology Regulate gut microbiota to treat neurodegenerative disorders
TW201821093A (zh) 2016-07-13 2018-06-16 英商４Ｄ製藥有限公司 包含細菌菌株之組合物
WO2018089794A1 (en) * 2016-11-11 2018-05-17 Arizona Board Of Regents On Behalf Of Arizona State University Methods and compositions for changing metabolite levels in a subject
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
US11147792B2 (en) 2017-05-15 2021-10-19 Axial Therapeutics, Inc. Inhibitors of microbially induced amyloid
KR20200019882A (ko) 2017-05-22 2020-02-25 4디 파마 리서치 리미티드 세균 균주를 포함하는 조성물
GB201708182D0 (en) * 2017-05-22 2017-07-05 4D Pharma Res Ltd Compositions comprising bacterial strains
TW201907931A (zh) 2017-05-24 2019-03-01 英商4D製藥研究有限公司 包含細菌菌株之組合物
JP6884889B2 (ja) 2017-06-14 2021-06-09 フォーディー ファーマ リサーチ リミテッド４Ｄ Ｐｈａｒｍａ Ｒｅｓｅａｒｃｈ Ｌｉｍｉｔｅｄ 細菌株を含む組成物
ES2917415T3 (es) 2017-06-14 2022-07-08 4D Pharma Res Ltd Composiciones que comprenden una cepa bacteriana
KR102218992B1 (ko) 2017-12-12 2021-02-23 한국생명공학연구원 아가토바쿨룸 속 균주를 유효성분으로 함유하는 자폐 범주성 장애의 예방, 개선 또는 치료용 조성물
JP2021518439A (ja) 2018-03-22 2021-08-02 アデア ファーマシューティカルズ エスアーエス 微生物組成物の新たな使用
US10980847B2 (en) * 2018-06-21 2021-04-20 Board Of Regents, The University Of Texas System Compositions and methods for detecting and treating brain injury associated fatigue and altered cognition (BIAFAC)
KR102121363B1 (ko) 2019-02-11 2020-06-10 대동폼웍스 주식회사 기능성 지지 구조체 및 그를 이용한 건축구조물 시공방법, 그리고 그 시공방법에 따라 시공된 건축구조물
KR20220034816A (ko) 2019-07-05 2022-03-18 4디 파마 리서치 리미티드 박테리아 균주를 포함하는 조성물
TW202140773A (zh) 2020-01-27 2021-11-01 英商4D製藥研究有限公司 包含細菌菌株之組成物
WO2022055871A1 (en) * 2020-09-11 2022-03-17 California Institute Of Technology Probiotic treatments for parkinson's disease
CN114699425B (zh) * 2022-02-16 2023-08-04 广州知易生物科技有限公司 脆弱拟杆菌的荚膜多糖a提取物的新应用
CN114699424B (zh) * 2022-02-16 2023-07-18 广州知易生物科技有限公司 脆弱拟杆菌两性离子荚膜多糖或/和改性的两性离子荚膜多糖的新应用
CN114699423B (zh) * 2022-02-16 2023-06-23 广州知易生物科技有限公司 脆弱拟杆菌的荚膜多糖提取物在制备防治精神分裂症的药物中的应用

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5443826A (en) 1988-08-02 1995-08-22 Borody; Thomas J. Treatment of gastro-intestinal disorders with a fecal composition or a composition of bacteroides and E. Coli
AUPM864894A0 (en) 1994-10-07 1994-11-03 Borody, Thomas Julius Treatment of bowel-dependent neurological disorders
US5951977A (en) 1997-10-14 1999-09-14 The United States Of America, As Represented By The Secretary Of Agriculture Competitive exclusion culture for swine
US7041814B1 (en) 1998-02-18 2006-05-09 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Enterobacter cloacae for diagnostics and therapeutics
US20040170617A1 (en) 2000-06-05 2004-09-02 Finegold Sydney M. Method of treating diseases associated with abnormal gastrointestinal flora
US20020013270A1 (en) 2000-06-05 2002-01-31 Bolte Ellen R. Method for treating a mental disorder
AUPQ899700A0 (en) * 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
US20040005304A1 (en) 2002-07-08 2004-01-08 Mak Wood, Inc. Novel compositions and methods for treating neurological disorders and associated gastrointestinal conditions
US7749509B2 (en) * 2003-08-29 2010-07-06 Cobb And Company, Llp Treatment of autism using probiotic composition
US7759105B2 (en) * 2003-08-29 2010-07-20 Cobb & Company, Llp Probiotic composition useful for dietary augmentation and/or combating disease states and adverse physiological conditions
US8192733B2 (en) 2003-08-29 2012-06-05 Cobb & Associates Probiotic composition useful for dietary augmentation and/or combating disease states and adverse physiological conditions
US7731976B2 (en) 2003-08-29 2010-06-08 Cobb And Company, Llp Treatment of irritable bowel syndrome using probiotic composition
US20060177424A1 (en) 2003-08-29 2006-08-10 Cobb Mark L Treatment of disease states and adverse physiological conditions utilizing anti-fungal compositions
WO2006059245A2 (en) 2004-11-16 2006-06-08 Neurochem (International) Limited Compounds for the treatment of cns and amyloid associated diseases
GB0504096D0 (en) 2005-02-28 2005-04-06 Tipogen As Method
JP2006265181A (ja) * 2005-03-24 2006-10-05 Univ Of Tsukuba 魚類感染症予防製剤、魚類用餌、菌株、魚類感染症予防方法
US20100233312A9 (en) 2005-04-11 2010-09-16 The Procter & Gamble Company Compositions comprising probiotic and sweetener components
WO2007133188A1 (en) * 2006-05-01 2007-11-22 Cobb & Company, Llp Treatment of disease states and adverse physiological conditions utilizing anti-fungal compositions
EP2211879B1 (en) 2007-10-26 2014-05-07 Brenda E. Moore Probiotic compositions and methods for inducing and supporting weight loss
ES2564179T3 (es) 2007-11-06 2016-03-18 Edison Pharmaceuticals, Inc. Derivados de 4-(p-quinonil)-2-hidroxibutanamida para tratamiento de enfermedades mitocondriales
US20110118135A1 (en) 2008-01-09 2011-05-19 State Matthew W Mutations in Contaction Associated Protein 2 (CNTNAP2) are Associated with Increased Risk for Ideopathic Autism
US20100160372A1 (en) 2008-11-13 2010-06-24 Link Medicine Corporation Treatment of proteinopathies using a farnesyl transferase inhibitor
US20120190566A1 (en) 2009-03-25 2012-07-26 Susan Lindquist Compositions and methods for inhibiting biofilms
US9050276B2 (en) 2009-06-16 2015-06-09 The Trustees Of Columbia University In The City Of New York Autism-associated biomarkers and uses thereof
US20110081320A1 (en) 2009-10-06 2011-04-07 Nubiome, Inc. Treatment/Cure of Autoimmune Disease
WO2011044516A2 (en) 2009-10-09 2011-04-14 Prothera, Inc. Compositions and methods comprising pediococcus for reducing at least one symptom associated with autism spectrum disease in a person diagnosed with an autism spectrum disease
CA2797787C (en) 2010-04-29 2019-07-09 Wisconsin Alumni Research Foundation Metabolic biomarkers of autism
US9707207B2 (en) 2010-05-26 2017-07-18 The United States Of America As Represented By The Department Of Veterans Affairs Method for diagnosing, preventing, and treating neurological diseases
CN102947441A (zh) 2010-06-01 2013-02-27 穆尔研究企业有限责任公司 来自拟杆菌属的细胞组分、其组合物和使用拟杆菌或其细胞组分的治疗方法
EP2590658A2 (en) 2010-07-08 2013-05-15 Katholieke Universiteit Leuven Compositions and methods for removal or destruction of amyloid fibril or amyloid adhesin comprising aggregates
SI3072524T1 (en) 2010-10-07 2018-04-30 California Institute Of Technology Probiotic anti-autism therapy
US20120237482A1 (en) 2011-03-18 2012-09-20 Juan Rodriguez Methods for treatment of neurological disorders by modulation of microglial activation
EP2785828B1 (en) 2011-12-01 2020-04-08 The University of Tokyo Human-derived bacteria that induce proliferation or accumulation of regulatory t cells
MX2014012362A (es) 2012-04-13 2015-05-07 Trustees Boston College Composición prebiótica y métodos de uso.
WO2013176774A1 (en) 2012-05-25 2013-11-28 Arizona Board Of Regents Microbiome markers and therapies for autism spectrum disorders
JP6679309B2 (ja) * 2012-08-29 2020-04-15 カリフォルニア インスティチュート オブ テクノロジー 自閉症スペクトラム障害の診断および処置
JP2016509003A (ja) 2013-02-04 2016-03-24 セレス セラピューティクス インコーポレイテッド 組成物および方法
WO2014121304A1 (en) 2013-02-04 2014-08-07 Seres Health, Inc. Compositions and methods
US9511100B2 (en) 2013-06-05 2016-12-06 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
FI127671B (en) 2014-05-28 2018-11-30 Filip Scheperjans Procedure for the diagnosis of Parkinson's disease
CN104546932A (zh) 2014-09-30 2015-04-29 深圳华大基因科技有限公司 卵形拟杆菌在治疗或预防类风湿性关节炎或其相关疾病中的应用
CA2966363A1 (en) 2014-10-30 2016-05-06 California Institute Of Technology Compositions and methods comprising bacteria for improving behavior in neurodevelopmental disorders
US10111914B2 (en) 2014-10-30 2018-10-30 California Institute Of Technology Compositions and methods comprising bacteria for improving behavior in neurodevelopmental disorders
WO2016069792A1 (en) 2014-10-30 2016-05-06 California Institute Of Technology Compositions and methods comprising bacteria for improving behavior in neurodevelopmental disorders
WO2016110768A1 (en) 2015-01-07 2016-07-14 Ecole Polytechnique Federale De Lausanne (Epfl) Gastro-intestinal biomarkers for diagnosis and therapies of proteinopathies
CN108243608A (zh) 2015-05-22 2018-07-03 亚利桑那大学董事会 用于治疗自闭症谱系障碍及相关症状的方法
WO2017205302A1 (en) 2016-05-23 2017-11-30 California Institute Of Technology Regulate gut microbiota to treat neurodegenerative disorders
EP3474862A1 (en) 2016-06-22 2019-05-01 ProDigest BVBA Microbial carotenoids affecting gut microbial composition
US10200089B2 (en) 2017-06-07 2019-02-05 General Electric Company Sensor system and method

Also Published As

Publication number Publication date
US20210069261A1 (en) 2021-03-11
EP3212207A4 (en) 2018-06-13
CA2966360A1 (en) 2016-05-06
JP2017535542A (ja) 2017-11-30
US10111914B2 (en) 2018-10-30
EP3212207A2 (en) 2017-09-06
US11202809B2 (en) 2021-12-21
AU2021232735A1 (en) 2021-12-23
US20220072065A1 (en) 2022-03-10
CN107106616A (zh) 2017-08-29
WO2016069795A3 (en) 2016-08-25
KR20170086492A (ko) 2017-07-26
CA2966360C (en) 2023-09-05
EP3998074A1 (en) 2022-05-18
HK1243639A1 (zh) 2018-07-20
AU2015339284B2 (en) 2021-08-05
US20190125809A1 (en) 2019-05-02
AU2015339284A1 (en) 2017-06-01
US11672837B2 (en) 2023-06-13
AU2015339284A8 (en) 2021-08-26
BR112017009004A2 (pt) 2017-12-19
WO2016069795A2 (en) 2016-05-06
US20160120917A1 (en) 2016-05-05
US10675310B2 (en) 2020-06-09

Similar Documents

Publication Publication Date Title
EA201790811A1 (ru) Содержащие бактерии композиции и способы для улучшения видов поведения при нарушениях неврологического развития
WO2016069801A8 (en) Compositions and methods comprising bacteria for improving behavior in neurodevelopmental disorders
MX2021014709A (es) Composiciones para usarse en el incremento de los niveles de globulos rojos y el tratamiento de enfermedad de celulas falciformes.
ECSP19044183A (es) (aza)indol-, benzotiofen, y benzofuran-3-sulfonamidas
CY1120035T1 (el) Πυριμιδοπυριμιδινονες χρησιμες ως αναστολεις της wee-1 κινασης
CL2018001621A1 (es) Heteroarilhidroxipirimidinonas como agonistas del receptor de apelina (apj)
EA201690969A1 (ru) Способы и композиции для лечения связанных со старением состояний
CO2018004968A2 (es) 2,4-dihidroxi-nicotinamidas como agonistas del receptor de apelina (apj)
TN2016000553A1 (en) Methods and compositions for treating ulcers
EA201590388A1 (ru) Способы лечения таупатии
EA201690881A1 (ru) Соединения-ингибиторы аутотаксина
BR112015026307A2 (pt) heterociclo bicíclicos como inibidores de fgfr
EA201690898A1 (ru) Способы лечения таупатии
EA201792437A1 (ru) Способы и композиции для лечения нарушений, ассоциированных со старением
EA201690007A1 (ru) Соединения, ингибирующие металлоферменты
BR112017021312A2 (pt) tratamento de câncer de pulmão com inibidores de glutaminase
EA201890811A1 (ru) Способы лечения мышечной дистрофии
EA201591278A1 (ru) Композиции, содержащие c1-inh, и способы профилактики и лечения расстройств, ассоциированых с дефицитом ингибитора с1 эстеразы
CY1120877T1 (el) Συνθεσεις και μεθοδοι για την αντιμετωπιση της κοιλιοκακης
EA201791182A1 (ru) Новые производные 2'- и/или 5'-аминокислотных эфиров фосфороамидатов 3'-дезоксиаденозина в качестве противораковых соединений
NZ748769A (en) Nitroxyl donors with improved therapeutic index
EA201790442A1 (ru) Трициклические азотсодержащие соединения для лечения инфекции, вызываемой neisseria gonorrhoeae
EA201790207A1 (ru) Новые замещенные пиримидиновые соединения
EA201892225A1 (ru) АНТИТЕЛА К ФАКТОРУ Bb КОМПЛЕМЕНТА И ИХ ПРИМЕНЕНИЕ
EA201891514A1 (ru) Комбинированная терапия ингибитором бромодомена и экстратерминального белка